These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 38330975)
1. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Yang Z; Li Z; Zhan Y; Lin Z; Fang Z; Xu X; Lin L; Li H; Lin Z; Kang C; Liang J; Liang S; Li Y; Li S; Yang X; Ye F; Zhong N; Lancet Infect Dis; 2024 May; 24(5):535-545. PubMed ID: 38330975 [TBL] [Abstract][Full Text] [Related]
2. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590 [TBL] [Abstract][Full Text] [Related]
4. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Haffizulla J; Hartman A; Hoppers M; Resnick H; Samudrala S; Ginocchio C; Bardin M; Rossignol JF; Lancet Infect Dis; 2014 Jul; 14(7):609-18. PubMed ID: 24852376 [TBL] [Abstract][Full Text] [Related]
5. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial. Zhan Y; Lin Z; Liang J; Sun R; Li Y; Lin B; Ge F; Lin L; Lu H; Su L; Xiang T; Pan H; Huang C; Deng Y; Wang F; Xu R; Chen D; Zhang P; Tong J; Wang X; Meng Q; Zheng Z; Ou S; Guo X; Yao H; Yu T; Li W; Zhang Y; Jiang M; Fang Z; Song Y; Chen R; Luo J; Kang C; Liang S; Li H; ; Zheng J; Zhong N; Yang Z EClinicalMedicine; 2024 Jan; 67():102359. PubMed ID: 38188690 [TBL] [Abstract][Full Text] [Related]
6. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Paton NI; Lee L; Xu Y; Ooi EE; Cheung YB; Archuleta S; Wong G; Wilder-Smith A Lancet Infect Dis; 2011 Sep; 11(9):677-83. PubMed ID: 21550310 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study. Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF; Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of GABA Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM; Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836 [TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
20. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Beigel JH; Aga E; Elie-Turenne MC; Cho J; Tebas P; Clark CL; Metcalf JP; Ozment C; Raviprakash K; Beeler J; Holley HP; Warner S; Chorley C; Lane HC; Hughes MD; Davey RT; Lancet Respir Med; 2019 Nov; 7(11):941-950. PubMed ID: 31582360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]